Evaluation of different MET genotypes as biomarkers for immunotherapy outcomes in NSCLC patients.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.e21032
Abstract: e21032 Background: Previous studies suggested that MET exon 14 ( METex14) mutation regarding as a distinct subset was sensitive to MET-inhibitors, but poorly response to immunotherapy. Conversly, MET non-exon-14 (non-ex14) mutations including those undetermined functions… read more here.
Keywords: ex14 mutations; nsclc patients; met non; metex14 ... See more keywords